RxDoctor Payments Data

Joseph Rutledge, MD

Interventional Pain Medicine · Lafayette, INNPI 1750709523

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (47.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by SPR Therapeutics, Inc at 51.6% of the total. Among interventional pain medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$95,658in general payments, 2019–2025

Across 693 payments — averaging $138.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SPR Therapeutics, Inc$49K
  • Biotronik NRO, Inc.$21K
  • Boston Scientific$6K
  • Tersera Therapeutics LLC$6K
  • Abbott$6K
  • AbbVie$2K
  • plus $6K from 38 others

What the payments were for

  • Consulting fees$45,59248%
  • Speaking & faculty fees$15,03316%
  • Travel & lodging$15,44416%
  • Food & beverage$19,58420%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,658 in reported general payments places this provider in the 95th percentile of 68 interventional pain medicine providers in Indiana.

See all interventional pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$377,339
Medicare patients
492
Services billed
8,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl51$40,593
Nurtec OdtRimegepant Sulfate15$15,586
QuliptaAtogepant11$12,008
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen580$11,445
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl78$11,268
Buprenorphine27$6,674
Gabapentin260$3,732
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen135$3,500
Lidocaine25$3,062
Pregabalin119$2,709
Buprenorphine Hcl41$1,831
Oxycodone Hcl74$1,506
Celecoxib32$1,115
Cephalexin156$1,072
Tramadol Hcl225$1,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$28$40,59351 claims
PfizerNurtec Odt$71$15,58615 claims
AbbVieQulipta$1,871$12,00811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 interventional pain medicine providers in Indiana.

Other interventional pain medicine in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →